Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
Top Cited Papers
Open Access
- 1 December 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (7), 598-607
- https://doi.org/10.1158/2159-8290.cd-11-0214
Abstract
Objective, long-lasting responses are observed in patients with NSCLC treated with azacitidine and entinostat.Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid TumorsClinical Cancer Research, 2009
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesBlood, 2009
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced CancersClinical Cancer Research, 2008
- The Epigenomics of CancerCell, 2007
- A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958